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The nanoparticles (NP) applications in industry and biomedicine are 
growing despite of superficial understanding about the mechanisms of 
NP biological interactions and the possible toxicity. The beneficial NP 
applications in medicine, as well as potential adverse effects, first of all 
depend on the NP accumulation and localization in the organism. The 
human in pre-natal stages is more sensitive to toxic materials than the 
adult organism and, therefore, it is physiologically protected from 
harmful agents by the selective transport across the placental barrier. 
However, there is a lack of studies on the NP penetration through this 
barrier and the accumulation in foetus.  
In this study fluorescence spectroscopy and confocal microscopy 
methods were employed to investigate the distribution of polyethylene 
glycol (PEG) coated semiconductor quantum dots (QD) in the pregnant 
rat model. The main results indicate that QD are systemically distributed 
in the body and can be found in all the investigated organs, including 
placenta and uterus 3 h after the intraperitoneal injection. However, QD 
could not be detected in the foetal tissues (embryo, yolk sac placenta, 
umbilical cord). The study shows that QD mainly accumulate in the 
maternal blood sinuses of the placenta and the QD passage to the foetus 
is prevented by the placental barrier.  
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INTRODUCTION 
Nanoparticles (NP) are organic and inorganic substances in the size 
range of 1–100 nm and humans have been exposed to such particles 
throughout their history. However, the industrial era dramatically 
changed sources, doses, and the types of NP. Nanotechnology is a 
rapidly developing field leading to an increase of engineered NP with 
conceptually new physical and chemical properties, which might induce 
novel effects in biological systems [6, 7]. The number of commercial 
NP-based products in food, cosmetics and medicine is expanding [1, 
15]. This phenomena raises concerns about NP accumulation, long-term 
retention in organism and the forthcoming toxic effects.  
Quantum dots (QD) are semiconductor NP in the size of 2–10 nm 
and they have superior optical properties when compared with organic 
dyes. QD have broad absorption spectra, bright photoluminescence 
(PL), they are photostable and can be easily chemically modified for 
biological functionalization. It was shown that QD can be toxic in vitro 
and in vivo and the adverse effects depends on QD physicochemical and 
environmental factors [3, 7, 10]. However, the biological interaction of 
NP mainly depend on their size and surface coating [4, 13] and these 
properties can be easily tuned in the case of QD. It makes QD a perfect 
model of NP to investigate the fundamental mechanisms of the NP 
biodistribution and physiological effects. 
The studies of the NP penetration through the placental barrier are 
important because of few aspects. Firstly, is the evaluation of possible 
embryotoxicity and teratogenicity of nanoagents. Secondly, the NP 
which do not pass to the foetus could be used as the drug delivery 
platform during pregnancy to avoid the effect on embryogenesis [11]. 
Finally, the specialized NP which permeate the placental barrier could 
be used for embryo-targeted prenatal diagnostics and therapy. By now 
there are only few in vivo studies on the NP accumulation in foetus and 
there is a lack of knowledge of general patterns of the NP transport 
across the maternal-foetal barrier. 
In this study we used the methods of fluorescence spectroscopy and 
confocal microscopy to investigate the accumulation of CdSe/ZnS PEG 
coated QD in the tissues of the pregnant rat and to evaluate their 
penetration across the placental barrier to the foetus. 
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MATERIALS AND METHODS 
Animal breading  
Albino  Wistar  rats (9–11 weeks old) were obtained from the State 
Research Institute Center of Innovative Medicine (Vilnius, Lithuania). 
Animals were housed under the conditions of constant temperature, 
humidity and the standard light /dark cycle (12 h/ 12 h). Food and fresh 
drinking water were available ad libitum. The study was approved by 
the Lithuanian Animal Care and Use Committee (No 0019; 2001–2005).  
After being acclimated for at least 7 days, female rats were mated 
overnight with the males of the same strain. Vaginal smears from each 
female rat were collected and subjected to microscopic examination on 
the following morning in order to determine the oestrous cycle and the 
presence of sperm. The day of sperm detection in vaginal smears was 
designated as day 0 of gestation.  
The CdSe/ZnS quantum dots coated with polyethylen glycol (PEG) 
were used for experiments (Qtracker-655, non-functionalized, 
Invitrogen Inc.). The stock solution was diluted up to 0.8 μM in saline 
and injected intraperitoneally on the day 18 of gestation. The animals of 
the control group were injected with pure saline.  
 
QD pharmacokinetics measurements 
The 50 µl blood samples were punctuated from the tail vein before 
(control sample) and after the QD injection (t: 0.5 – 24 h). In total 4 
animals were used for the experiments. The blood was instantly mixed 
with 50 µl heparin solution to prevent coagulation. The solution was 
diluted up to 1.5 ml with saline and centrifuged for 10 min at 1500 rcf. 
The supernatant was used for fluorescence spectroscopy. The relative 
QD concentration in the blood plasma was assessed by subtracting the 
autofluorescence spectra and evaluating the PL intensity at the peak. 
The data from different experiments (n=4) was normalized to the 
maximum intensity and averaged. The averages were fitted using the 
biphasic dose response model (1): 
 
y(x) =A1 / (1 + 10^(( b1–x) * h1)) + A2 / (1 + 10^((b2–x) * h2)),   (1) 
x – independent variable (time), A1,2, b1,2, h1,2 – fitting parameters. 
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Fluorescence spectroscopy 
3 h after injection all the rats were subjected to the Caesarean section in 
the state of neuroleptoanalgesia (Calipsol 0.5 ml per one rat) on day 18 
[8]. The internal organs, including uterus with the formed embryos, 
were removed. The excised organs were washed in saline and drained.  
The fluorescence spectra were measured using the Varian Cary 
Eclipse spectrometer coupled with the fiber optics module. The blood 
solution samples were measured using the standard 1 cm plastic 
cuvettes. The excitation light of 480 nm was used. 
 
Sample preparation and fluorescence microscopy 
The internal organs including uterus, placenta and embryo were sectio-
ned using the cryomicrotome setup. The section slides were divided in 
two groups: untreated and stained with haematoxylin/eosin (HE). The 
analysis was performed using the Nikon Eclipse TE-2000 fluorescence 
microscope with C1 confocal scanning system (objectives x10/0.7 and 
x60/1.4 Plan Apo VC oil). The argon ion laser was used for the 




After the intaperitoneal injection, the QD presence in the blood plasma 
was observed after 15 minutes by the means of fluorescence micro-
scopy. The QD concentration reached its maximum after ~2.5 h and 
started to decrease afterwards (Figure 1.). After 24 h QD could not be 
detected in the blood plasma indicating their clearance from blood 
and/or degradation. The increase is associated to the QD absorption 
from the intraperitoneal space via the lymphatic or blood vessels. The 
QD decrease is thought to be mainly determined by the uptake of the 
reticuloendothelial system and accumulation in tissues [4]. 
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Figure 1. The kinetics of QD concentration in the blood plasma of the 
pregnant rat after the intraperitoneal injection. The data are represented as 
the mean ± standard deviation from n= 4 animals. 
 
The QD incubation interval of 3 h hours was selected for the evaluation 
of QD distribution in tissues as it represents the maximum likelihood to 
detect QD by means of fluorescence techniques. QD accumulation in 
tissues was evaluated by means of fluorescence spectroscopy. The 
characteristic QD PL was seen in the spectra of all the investigated 
organs, including liver, lungs, muscle, heart, thymus, etc. These results 
indicate that QD were distributed systemically due to blood circulation. 
QD could also be detected in the uterus and placenta tissues (Figure 
2.). However QD PL was not registered in the embryonic tissues: 
embryo, yolk sac placenta and umbilical cord. The fluorescence of the 
yolk sac placenta surrounding the embryo is mainly addressed to the PL 
peak at 619 nm which is attributed to the endogenous porphyrins (Figure 
3.). The porphyrin accumulation in the pregnant rat was observed earlier 
[5].   Nanoparticles distribution in pregnant rat 223 
 
 
Figure 2. The fluorescence spectra of rat tissues indicating the presence of 
QD in the maternal tissues (uterus, placenta) 3 h after the QD injection. 
 
Microscopic analysis of tissue samples 
The cryotome dissection was used to prepare tissue slides for the 
microscopy analysis. The prepared samples were described by histo-
logical examination using the standard HE staining technique under low 
magnification (Figure 3). In the sample of placenta the characteristic 
structures of decidua, junctional zone and labyrinthine zone layers are 
easily identified.  
 
 
Figure 3. The H&E stained cryosections of the placenta (the labyrinthine 
zone) and the embryo, objective x10/0,25. 224  V. Kulvietis et. al. 
The unstained slides were used to investigate the QD localization. The 
confocal microscope coupled with a spectral detector enables the 
discrimination of the QD PL from the tissue autofluorescence with high 
spectral resolution. This technique revealed that QD are accumulated in 
the labyrinthine zone of the placenta (Figure 4). QD appeared 
distributed in the samples not homogenously, but patterned, indicating 
QD accumulation in the areas with a lower autofluorescence background 
(represented green). In the labyrinthine zone the maternal blood sinuses 
lack of endogenous fluorophores which are more abundant in the 
connective foetal tissue, therefore maternal blood results in lower 
fluorescence intensity and darker areas in the image when compared 
with foetal tissue. In this way, QD are mostly distributed in the maternal 
blood sinuses.  
 
 
Figure 4. Confocal microscopy image of the rat placenta (labyrinthine 
zone) and the embryo tissue slides 3 h after QD injection. The patterned red 
distribution of QD PL (at 650 nm) in the placenta is mainly attributed to the 
tn the maternal blood sinuses of the placenta. The characteristic QD PL was 
not registered in the embryo sample, objective x60/1,4.   Nanoparticles distribution in pregnant rat 225 
 
The examination of the embryo tissues showed no appearance of QD PL 
in the samples. Some yellowish fluorescent endogenous fluorophores 
were seen, but the PL spectra were distinct from the QD PL spectra 
found in the placenta. These results confirm the spectroscopic findings. 
 
DISCUSSION 
By now there are only few in vivo studies on nanoparticles (NP) 
penetration through the placental barrier and the forthcoming 
accumulation in the foetus. Recently Chu M et al. investigated the 
transplacental transport of thiol-capped CdTe QD in mice [3]. Twenty-
four hour after intravenous administration the highest QD accumulation 
was registered in liver and spleen, while the cadmium concentration in 
the foetus reached only 0.6% of the injected dose. The fluorescence 
microscopy technique was unable to detect QD in the embryonic tissues. 
The surface stabilization with polyethylene glycol (PEG) or SiO2 
decreased QD uptake to the puppies. The embryotoxic effects of QD 
were found to be dependent on the cadmium dose in the foetus. 
However, the authors indicate that the performed mass spectrometry 
assay was not able to discriminate between QD and free cadmium ions, 
therefore it is not possible to say if QD penetrated the placental barrier 
or they were degraded in the maternal organism and the formed 
cadmium ions were transported to the foetus [3]. 
Another study reported pregnancy complications in mice induced by 
the silica and titanium dioxide (TiO2) nanoparticles [15]. The whole-
body optical imaging analysis showed the accumulation of fluorescently 
labelled 70 nm size silica and 143 nm size TiO2 NP in placenta 24 hours 
after intravenous NP injection. However the most intense fluorescence 
for all NP was observed in the liver. Electron microscopy revealed that 
NP were localized in the trophoblast cells of the placenta, as well as in 
the foetal liver and foetal brain tissues. The quantitative analysis was not 
performed. However, the silica NP of bigger size – 300 nm or 1000 nm 
– were not observed in the placenta or foetuses. The NP induced adverse 
effects on the embryo development such as growth inhibition, 
resorptions, placental dysfunction and other functional changes. The 
observed physiological changes were related to the NP penetration 
across the barrier and they were not induced using the 300 nm and 1000 
nm NP [15].  226  V. Kulvietis et. al. 
The lack of in vivo studies on NP transplacental passage and the 
disambiguous results of different groups raise the need for additional 
investigations on physiological NP effects to embryogenesis. Our results 
show that fluorescence spectroscopy and confocal microscopy methods 
can be used to investigate the accumulation and pharmacokinetics of 
fluorescent nanoparticles in the experimental animals. The main 
findings indicate that 3 hours after intraperitoneal QD injection they are 
systemically distributed throughout the organism with blood circulation 
and can be found in all the organs, including the uterus and the placenta. 
High QD concentration in blood resulted in the QD appearance in the 
maternal sinuses of the placenta. However, they were not detected in the 
foetal tissues using fluorescence spectroscopy and microscopy techni-
ques. It shows that the QD penetration across the placental barrier is 
highly limited. According to ex vivo studies, the dendrimers appear in 
the foetal compartment already 15 min after the NP addition to the 
maternal perfusate [11] and their concentration keeps rising up to 6 h. 
The concentration of polystyrene NP in the foetal compartment was 
saturated after 3 h of perfusion [14]. These data indicate that the period 
of 3 h used in our experiments should be sufficient for QD to penetrate 
across the placental barrier.  
It was also shown that the PEG coated gold NP accumulated in the 
placenta without passing to the foetal tissue [12]. Different ex vivo 
studies on human models showed that the NP penetration through the 
placental barrier highly depends on the size and the surface coating of 
the NP [11, 12, 14]. We used PEG coated QD which increases the 
overall size of the nanoparticles and minimizes the interactions with 
biomolecules. The increase in size reduces the passive passage of NP 
through the biological barriers [2] and the NP interactions with proteins 
are essential for NP cellular adhesion and the forthcoming endocytosis 
by the trophoblast cells [9, 13]. Therefore the PEG coating could result 
in the lower QD transplacental passage. 
It is worth mentioning, that the QD PL intensity remained stable 
during fluorescence imaging which is not characteristic of the 
conventional organic dyes used for fluorescence microscopy. The effect 
of photo bleaching is one of the main limitations in fluorescence-based 
methods and it can be overcome using the semiconductor QD. 
For conclusion, PEG coated CdSe/ZnS quantum dots distributed 
systemically in the body of the pregnant rat 3 h after the intraperitoneal   Nanoparticles distribution in pregnant rat 227 
 
injection and accumulated in all the investigated organs, including the 
uterus and the placenta. Fluorescence microscopy revealed that QD 
mainly accumulate in the maternal blood sinuses of the placenta, but 
they were not found in the foetal tissues. The fluorescence-based 
investigations show that the NP passage to the foetus is prevented by the 
placental barrier. Further studies using the particles of different sizes 
and materials are naturally needed in order to conclusively evaluate the 
mechanisms of the NP transplacental transport and to extract the 
knowledge on possible adverse or beneficial effects of the NP 
application in medicine. 
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